Macrogen, Inc. provides precision medicine and bio-engineering healthcare services in Korea and internationally. It offers personal healthcare services, including disease prediction and wellness genetic, and DTC genetic testing services; MyPETGENE, a genetic testing service for companion animals; clinical services, such as precision medicine, genetic testing for cancer risk, NGS-based genetic panel lab, and GCLP services; and single cell expert services comprising single cell multi-omics and spatial transcriptome analysis, and single cell (In Situ/spatial) services. The company also provides whole genome, whole exome, transcriptome, epigenome, and metagenome sequencing services; standard sequencing, identification, fragment, customized sequencing, and human ID services; expression, genome, and epigenome microarray; proteomics olink; gene synthesis; DNA and RNA oligo synthesis, and peptide synthesis; and CRISPR knock-in/out, GEM, and mass production services. Macrogen, Inc. was founded in 1997 and is based in Seoul, South Korea.